PDCD1 and neoplasm: Combination treatment of RR-CDA and anti-PD-1 led to a 78.2% decrease in tumor burden and a 83.4% reduction in the volume of malignant ascites, in some cases resulting in the complete eradication of peritoneal tumors and ascites (figure 6C).